Byline
Amino Wire Editorial Team
The Amino Wire Editorial Team is the site's news and explainer desk. It reports regulatory, enforcement and court actions affecting the peptide market, writes the lab-testing explainers, and reviews every page against the primary records it cites (FDA, DOJ, Federal Register, court filings) or named reputable press, with dates. It is an editorial team, not a medical or legal practice.
Stories
27- NSW: 1,180 peptide-linked ER visits, most name retatrutide
- Lilly drops two more retatrutide suits, both with prejudice
- CSPI urges FDA to overrule advisers on six peptides
- Peptide access policy goes to White House review
- Jury convicts Pinned Aminos 'research compounds' seller
- FDA sends warning letters to five online peptide sellers
- Paradigm Peptides owner sentenced to 70 months in prison
- FDA advisers back six peptides for 503A list, reject DSIP
- Michigan man gets 21 months for 'research' semaglutide sales
- Louisiana bars boards from blocking compounded peptides
- FDA plans panel on LL-37, GHK-Cu, Melanotan II and more
- FDA removes 12 peptides from Category 2; review set for July
- Utah doctor indicted over China-sourced, relabeled peptides
- FDA warns two sellers of retatrutide as a ‘research peptide’
- Peptide Sciences shuts down; notice gives no reason
- Kennedy on Rogan: ‘I’m a big fan of peptides’
- FDA says it will act against mass-marketed compounded GLP-1s
- Science.bio permanently closes research-chemical store
- WADA's 2026 Prohibited List names BPC-157, TB-500 and MOTS-c
- FDA warns online GLP-1 sellers over retatrutide and claims
- Kentucky doctor pleads guilty over 'research' semaglutide
- FDA warns USApeptide.com over semaglutide and tirzepatide
- FDA ends semaglutide shortage; compounding wind-down set
- FDA again declares the tirzepatide shortage resolved
- ‘Research use only’ labels did not stop FDA warning letters
- FDA advisers reject CJC-1295, AOD-9604 and thymosin alpha-1
- FDA advisers reject ipamorelin, kisspeptin-10, ibutamoren
Explainers
21Regulation
- Are peptides legal? What US law actually says in 2026
- FDA Category 2 peptides: the list, the reasons, and the 2026 changes
- 503A vs 503B: the two legal lanes for compounded peptides
- ‘Research use only’: what the label does, and what it doesn’t
- Is BPC-157 legal? Its FDA status, step by step
- FDA warning letters to peptide sellers: what they are and how to read one
- Importing peptides: what FDA’s import rules say
- Compounded semaglutide and tirzepatide after the shortages ended
- Peptides and anti-doping: which are banned under WADA’s 2026 list
- FDA status by peptide: approval, compounding category, advisory votes and sport
- Peptide laws by state: what states can and can't change, and what's actually on the books
- FDA Category 1 peptides: which ones are on it and what Category 1 allows
- How a peptide gets on FDA's 503A bulks list: nomination, PCAC vote, rulemaking
- FDA's 'Interim Access Policy' for compounded peptides: what is known and what it could mean
Testing
- How third-party peptide testing works, from vial to certificate
- HPLC purity: what the percentage on a peptide COA means
- Mass spectrometry: how labs confirm a peptide is what the label says
- Net peptide content: why a ‘10 mg’ vial may not hold 10 mg of peptide
- Endotoxin testing: the test a purity number can’t replace
- Sterility testing: what it detects and what a ‘pass’ means
- How to verify a peptide COA in seven checks